| 24/06/24 | 07:00:03 | 24 Jun 2024 | | European Commission Approval for FRUZAQLA |
| 17/06/24 | 07:00:12 | 17 Jun 2024 | | Lancet Publish Phase III ESLIM-01 Results |
| 07/06/24 | 07:00:11 | 7 Jun 2024 | | HUTCHMED Initiates Phase I Trial of HMPL-506 |
| 03/06/24 | 07:00:12 | 3 Jun 2024 | | Nature Medicine Publish Phase III FRUTIGA Results |
| 31/05/24 | 09:30:00 | 31 May 2024 | | Total Voting Rights |
| 24/05/24 | 07:00:09 | 24 May 2024 | | HUTCHMED Presentations at 2024 ASCO Annual Meeting |
| 17/05/24 | 15:00:00 | 17 May 2024 | | Retirement of Chairman and new Chairman appointed |
| 17/05/24 | 07:00:11 | 17 May 2024 | | HUTCHMED Data to be Presented at EHA2024 Congress |
| 14/05/24 | 07:00:14 | 14 May 2024 | | HUTCHMED Initiates Registrational Phase III Trial |
| 14/05/24 | 07:00:14 | 14 May 2024 | | HUTCHMED Initiates Phase II/III Trial with Hengrui |
| 10/05/24 | 13:00:00 | 10 May 2024 | | Result of AGM |
| 08/05/24 | 09:30:00 | 8 May 2024 | | Directorate Change |
| 26/04/24 | 13:30:00 | 26 Apr 2024 | | Positive CHMP Opinion for Fruquintinib |
| 22/04/24 | 09:30:01 | 22 Apr 2024 | | Vesting of Awards Under the LTIP |
| 08/04/24 | 09:30:00 | 8 Apr 2024 | | 2023 Annual Report and Notice of AGM |
| 05/04/24 | 09:30:01 | 5 Apr 2024 | | Data to be Presented at AACR Congress 2024 |
| 02/04/24 | 07:00:16 | 2 Apr 2024 | | HUTCHMED and Innovent Announce NDA Acceptance |
| 28/03/24 | 07:00:16 | 28 Mar 2024 | | Savolitinib sNDA Accepted in China |
| 22/03/24 | 07:00:11 | 22 Mar 2024 | | Initiation of Registration Stage of P2/3 Trial |
| 14/03/24 | 09:00:00 | 14 Mar 2024 | | LTIP and Share Option Scheme |
| 05/03/24 | 08:30:00 | 5 Mar 2024 | | Vesting of awards under the LTIP |
| 28/02/24 | 12:45:00 | 28 Feb 2024 | | Publication of Form 20-F |
| 28/02/24 | 11:30:01 | 28 Feb 2024 | | 2023 Full Year Results and Business Updates |
| 07/02/24 | 07:00:07 | 7 Feb 2024 | | Presentation of Phase III Data on Fruquintinib |
| 02/02/24 | 08:37:31 | 2 Feb 2024 | | Inmagene Exercises Option for Two Drug Candidates |
| 01/02/24 | 08:30:00 | 1 Feb 2024 | | HUTCHMED to Announce 2023 Final Results |
| 30/01/24 | 07:12:09 | 30 Jan 2024 | | HUTCHMED Receives Marketing Approval in Hong Kong |
| 11/01/24 | 07:00:05 | 11 Jan 2024 | | Sovleplenib NDA Granted Priority Review in China |
| 29/12/23 | 08:30:00 | 29 Dec 2023 | | Total Voting Rights |
| 29/12/23 | 08:30:00 | 29 Dec 2023 | | Blocklisting Six Monthly Return |
| 21/12/23 | 10:00:02 | 21 Dec 2023 | | Overseas Regulatory Announcement |
| 13/12/23 | 07:00:21 | 13 Dec 2023 | | Inclusion in National Reimbursement Drug List |
| 13/12/23 | 07:00:20 | 13 Dec 2023 | | Completed Enrollment of Phase II/III Trial |
| 07/12/23 | 10:04:09 | 7 Dec 2023 | | Overseas Regulatory Announcement |
| 01/12/23 | 07:00:11 | 1 Dec 2023 | | Clinical Data to be Presented at Congresses |
| 30/11/23 | 08:30:00 | 30 Nov 2023 | | Total Voting Rights |
| 09/11/23 | 07:00:17 | 9 Nov 2023 | | U.S. FDA Approval of FRUZAQLA™ (fruquintinib) |
| 24/10/23 | 09:30:00 | 24 Oct 2023 | | Vesting of awards under the LTIP |
| 16/10/23 | 09:30:00 | 16 Oct 2023 | | Clinical Data to be Presented at ESMO 2023 |
| 29/09/23 | 09:30:02 | 29 Sept 2023 | | NDA Submission for Fruquintinib in Japan |
| 29/09/23 | 09:30:02 | 29 Sept 2023 | | Total Voting Rights |
| 14/09/23 | 09:30:03 | 14 Sept 2023 | | Director’s Share Dealing |
| 12/09/23 | 09:30:02 | 12 Sept 2023 | | Phase IIIb Savolitinib Results at WCLC 2023 |
| 12/09/23 | 07:00:07 | 12 Sept 2023 | | Patient Enrollment Completed for Bridging Study |
| 31/08/23 | 09:30:02 | 31 Aug 2023 | | Total Voting Rights |
| 29/08/23 | 07:00:08 | 29 Aug 2023 | | BTD in China for Savolitinib for Gastric Cancer |
| 21/08/23 | 07:00:04 | 21 Aug 2023 | | Sovleplenib Phase 3 Study Meets Primary Endpoint |
| 07/08/23 | 09:30:01 | 7 Aug 2023 | | Exercise of Share Options by a Director |
| 31/07/23 | 12:00:01 | 31 Jul 2023 | | Interim Results and Business Updates |
| 20/07/23 | 07:00:09 | 20 Jul 2023 | | Breakthrough Therapy Designation for Fruquintinib |
